Clinical trial
An Open-label, Active-controlled, Parallel and Dose-escalation, Phase 1 Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Intramuscular (IM) and Subcutaneous (SC) Donepezil (GB-5001) Injections Versus Donepezil Oral Tablet (Aricept®) in Healthy Male Volunteers
NCT06127368 is registered in ClinicalTrials.gov with G2GBio, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-label, Active-controlled, Parallel and Dose-escalation, Phase 1 Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Intramuscular (IM) and Subcutaneous (SC) Donepezil (GB-5001) Injections Versus Donepezil Oral Tablet (Aricept®) in Healthy Male Volunteers
- Lead sponsor
- G2GBio, Inc.
- Phase
- Phase 1
- Overall status
- Unknown status
- Start date
- January 3, 2024
- Completion date
- January 14, 2025
- Enrollment
- 56 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.